The continuous need for drug design and synthesis require novel high-throughput approaches for identifying and validating new drug targets. European scientists developed novel tools for discovering new drugs.
Receptors constitute attractive candidates for drug discovery since they receive signals from the environment and are implicated in disease. Diabetes and obesity remain a serious global problem, necessitating the development of novel interventions or preventative treatments. The scope of the EU-funded DDIPI (Drug discovery in interacting proteins) project was to identify compounds that bind to disease-associated receptors and inhibit their activity.
Further details: New era in drug design